Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Teva
Daiichi Sankyo
QuintilesIMS
Cipla
Johnson and Johnson
Boehringer Ingelheim
Deloitte
Chinese Patent Office

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021999

« Back to Dashboard

NDA 021999 describes INVEGA, which is a drug marketed by Janssen Pharms and is included in three NDAs. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the INVEGA profile page.

The generic ingredient in INVEGA is paliperidone palmitate. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.
Summary for 021999
Tradename:INVEGA
Applicant:Janssen Pharms
Ingredient:paliperidone
Patents:0
Therapeutic Class:Antipsychotics
Formulation / Manufacturing:see details
Pharmacology for NDA: 021999
Suppliers and Packaging for NDA: 021999
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999 NDA Patriot Pharmaceuticals, LLC 10147-0951 N 10147-0951-3
INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999 NDA Patriot Pharmaceuticals, LLC 10147-0952 N 10147-0952-1

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength3MG
Approval Date:Dec 19, 2006TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength6MG
Approval Date:Dec 19, 2006TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength9MG
Approval Date:Dec 19, 2006TE:ABRLD:Yes

Expired US Patents for NDA 021999

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999-003 Dec 19, 2006 ➤ Sign Up ➤ Sign Up
Janssen Pharms INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999-004 Dec 19, 2006 ➤ Sign Up ➤ Sign Up
Janssen Pharms INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999-001 Dec 19, 2006 ➤ Sign Up ➤ Sign Up
Janssen Pharms INVEGA paliperidone TABLET, EXTENDED RELEASE;ORAL 021999-006 Aug 26, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Merck
Medtronic
Boehringer Ingelheim
AstraZeneca
UBS
Fuji
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.